Arecor Therapeutics Statistics

Total Valuation

Arecor Therapeutics has a market cap or net worth of GBP 28.88 million. The enterprise value is 26.62 million.

Market Cap	28.88M
Enterprise Value	26.62M

Important Dates

The next estimated earnings date is Friday, December 27, 2024.

Earnings Date	Dec 27, 2024
Ex-Dividend Date	n/a

Share Statistics

Arecor Therapeutics has 37.76 million shares outstanding. The number of shares has increased by 0.98% in one year.

Current Share Class	n/a
Shares Outstanding	37.76M
Shares Change (YoY)	+0.98%
Shares Change (QoQ)	+0.00%
Owned by Insiders (%)	7.95%
Owned by Institutions (%)	37.79%
Float	25.20M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.78
PB Ratio	4.61
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-3.07
EV / Sales	5.43
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-4.69

Financial Position

The company has a current ratio of 1.37, with a Debt / Equity ratio of 0.06.

Current Ratio	1.37
Quick Ratio	1.08
Debt / Equity	0.06
Debt / EBITDA	n/a
Debt / FCF	-0.05
Interest Coverage	-535.35

Financial Efficiency

Return on equity (ROE) is -94.76% and return on invested capital (ROIC) is -60.72%.

Return on Equity (ROE)	-94.76%
Return on Assets (ROA)	-37.31%
Return on Capital (ROIC)	-60.72%
Revenue Per Employee	97,980
Profits Per Employee	-173,320
Employee Count	50
Asset Turnover	0.32
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -57.26% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-57.26%
50-Day Moving Average	72.69
200-Day Moving Average	111.53
Relative Strength Index (RSI)	40.92
Average Volume (20 Days)	11,384

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Arecor Therapeutics had revenue of GBP 4.90 million and -8.67 million in losses. Loss per share was -0.28.

Revenue	4.90M
Gross Profit	4.90M
Operating Income	-9.10M
Pretax Income	-8.94M
Net Income	-8.67M
EBITDA	-8.88M
EBIT	-9.10M
Loss Per Share	-0.28

Full Income Statement

Balance Sheet

The company has 2.55 million in cash and 280,000 in debt, giving a net cash position of 2.27 million or 0.06 per share.

Cash & Cash Equivalents	2.55M
Total Debt	280,000
Net Cash	2.27M
Net Cash Per Share	0.06
Equity (Book Value)	5.08M
Book Value Per Share	0.17
Working Capital	1.71M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -5.58 million and capital expenditures -93,000, giving a free cash flow of -5.68 million.

Operating Cash Flow	-5.58M
Capital Expenditures	-93,000
Free Cash Flow	-5.68M
FCF Per Share	-0.15

Full Cash Flow Statement

Margins

Gross margin is 100.00%, with operating and profit margins of -185.77% and -176.89%.

Gross Margin	100.00%
Operating Margin	-185.77%
Pretax Margin	-182.45%
Profit Margin	-176.89%
EBITDA Margin	-181.28%
EBIT Margin	-185.77%
FCF Margin	-115.88%

Dividends & Yields

Arecor Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.98%
Shareholder Yield	-0.98%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Arecor Therapeutics has an Altman Z-Score of -1.65. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.65
Piotroski F-Score	n/a